



Xencor to Participate in Upcoming Investor Conferences

April 1, 2019

MONROVIA, Calif.--(BUSINESS WIRE)--Apr. 1, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in two upcoming conferences:

- **Jefferies 6th Annual IO Cell Therapy Summit**

Date: Friday, April 5, 2019

Location: Boston, MA

- **18th Annual Needham Healthcare Conference**

Date: Tuesday, April 9, 2019

Presentation Time: 2:10 p.m. ET

Location: New York, NY

A live webcast of the Needham Healthcare Conference presentation will be available under "Events & Presentations" in the Investors section of the Company's website located at <https://investors.xencor.com/events.cfm>. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 90 days following the event.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases. Currently, 12 candidates engineered with Xencor's XmAb[®] technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190401005858/en/>

Source: Xencor, Inc.

Charles Liles
626-737-8118
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com